Interaction between HLA-DRB1*04 and HLA-DRB1*13 with respect to vascular events and antiphospholipid antibodies (aPL) in all patients
| Outcome | HLA-DRB1allele combinations | Number +/− for outcome | OR (95% CI) | p Value | Interaction measure (AP) (95% CI) | |
|---|---|---|---|---|---|---|
| Any vascular event | No*04 | No*13 | 91/237 | 1.0 (ref) | ||
| *04 | No*13 | 53/118 | 1.17 (0.78 to 1.75) | |||
| No*04 | *13 | 52/88 | 1.54 (1.01 to 2.34) | 0.04 | ||
| *04 | *13 | 15/11 | 3.55 (1.57 to 8.02) | 0.001 | 0.52 (0.10 to 0.94)† | |
| Any arterial event | No*04 | No*13 | 63/265 | 1.0 (ref) | ||
| *04 | No*13 | 36/135 | 1.12 (0.71 to 1.78) | |||
| No*04 | *13 | 30/110 | 1.15 (0.70 to 1.87) | |||
| *04 | *13 | 12/14 | 3.61 (1.59 to 8.17) | 0.001 | 0.65 (0.32 to 0.98)† | |
| Ischaemic cerebrovascular disease | No*04 | No*13 | 29/299 | 1.0 (ref) | ||
| *04 | No*13 | 24/147 | 1.68 (0.95 to 3.00) | 0.07 | ||
| No*04 | *13 | 16/124 | 1.33 (0.70 to 2.54) | |||
| *04 | *13 | 9/17 | 5.46 (2.23 to 13.34) | 4.4×10−5 | 0.63 (0.27 to 0.99)† | |
| Venous thromboembolism | No*04 | No*13 | 45/283 | 1.0 (ref) | ||
| *04 | No*13 | 28/143 | 1.23 (0.74 to 2.06) | |||
| No*04 | *13 | 28/112 | 1.57 (0.94 to 2.64) | 0.09 | ||
| *04 | *13 | 6/20 | 1.88 (0.72 to 4.95) | 0.04 (−0.94 to 1.0) | ||
| aβ2GP1 IgG§ | No*04 | No*13 | 42/303 | 1.0 (ref) | ||
| *04 | No*13 | 54/114 | 3.21 (2.03 to 5.08) | |||
| No*04 | *13 | 35/105 | 2.26 (1.37 to 3.73) | 0.001 | ||
| *04 | *13 | 13/13 | 6.79 (2.95 to 15.63) | 5.0×10−7 | 0.34 (−0.21 to 0.89) | |
| aCL IgG§ | No*04 | No*13 | 50/277 | 1.0 (ref) | ||
| *04 | No*13 | 48/120 | 2.22 (1.41 to 3.48) | |||
| No*04 | *13 | 35/105 | 1.85 (1.13 to 3.00) | 0.01 | ||
| *04 | *13 | 12/14 | 4.75 (2.08 to 10.87) | 6.9×10–5 | 0.355 (−0.19 to 0.90) | |
| aCL IgM§ | No*04 | No*13 | 58/269 | 1.0 (ref) | ||
| *04 | No*13 | 50/118 | 1.97 (1.27 to 3.04) | |||
| No*04 | *13 | 34/106 | 1.49 (0.92 to 2.40) | |||
| *04 | *13 | 9/17 | 2.46 (1.04 to 5.78) | 0.03 | 0.001(−0.89 to 0.89) | |
| aPT IgG‡ | No*04 | No*13 | 27/261 | 1.0 (ref) | ||
| *04 | No*13 | 25/127 | 1.90 (1.06 to 3.41) | |||
| No*04 | *13 | 21/108 | 1.88 (1.02 to 3.47) | 0.04 | ||
| *04 | *13 | 7/17 | 3.98 (1.51 to 10.45) | 0.003 | 0.30 (−0.39 to 1.0) | |
| >2aPL§ | No*04 | No*13 | 46/281 | 1.0 (ref) | ||
| *04 | No*13 | 51/117 | 2.66 (1.69 to 4.19) | |||
| No*04 | *13 | 33/107 | 1.88 (1.14 to 3.10) | 0.01 | ||
| *04 | *13 | 12/14 | 5.23 (2.27 to 12.03) | 2.1×10−5 | 0.32 (−0.25 to 0.89) | |
| Lupus anticoagulant¶ | No*04 | No*13 | 24/153 | 1.0 (ref) | ||
| *04 | No*13 | 28/66 | 2.71 (1.46 to 5.01) | |||
| No*04 | *13 | 17/58 | 1.87 (0.94 to 3.73) | 0.07 | ||
| *04 | *13 | 9/8 | 7.17 (2.52 to 20.39) | 3.7×10−5 | 0.50 (−0.02 to 1.0) | |
†Significant interaction.
‡Number investigated (N)=593.
§N=661.
¶Only analysed in the Stockholm group, N=363.
a, anti; AP, attributable proportion due to interaction; ≥2aPL, at least two positive tests of aβ2GP-1, aCL IgG and aCL IgM; β2GP1, β2-glycoprotein1; CL, cardolipin; Ig, immunoglobulin; PT, prothrombin; +/−, positive/negative.